Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis
Introduction Achieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for t...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/9/e026136.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846150458146553856 |
|---|---|
| author | Jinhui Tian Guanlin Yang Zhen Hua Peng Xu Feng-Ting Zhai Cheng-Fei Gao Fan Zhang Si-jia Liu Kun Dong Xiao-Feng Du |
| author_facet | Jinhui Tian Guanlin Yang Zhen Hua Peng Xu Feng-Ting Zhai Cheng-Fei Gao Fan Zhang Si-jia Liu Kun Dong Xiao-Feng Du |
| author_sort | Jinhui Tian |
| collection | DOAJ |
| description | Introduction Achieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for treatment. This study aims to examine the comparative effectiveness and safety of oral Chinese patent medicines for UAP on the national essential drugs list of China.Methods and analysis We will conduct a network meta-analysis (NMA) of all randomised controlled trials to evaluate the use of oral Chinese patent medicines as adjuvant for the treatment of UAP. We will explore eight electronic databases from their inception to June 2018 and search for grey literature. Primary outcomes include mortality and the cardiovascular events. Secondary outcomes include: (1) symptom improvement; (2) ECG improvement; (3) frequency of acute angina attack; (4) duration of angina; (5) adverse effects. Two independent authors will screen titles and abstracts, review full texts, extract data, assess the risk of bias using the Cochrane risk of bias tool and assess the quality of evidence and strength of the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). If adequate data are available, NMA will be performed with Bayesian analysis methods.Ethics and dissemination The NMA will help us to reduce the uncertainty of interventions and help clinicians to make optimal and more accurate therapeutic decisions for adults with UAP. Therefore, we will publish the findings of this study in a peer-reviewed journal. No ethics approval is necessary for this study based on the nature of its design.Trial registration number CRD42018092822. |
| format | Article |
| id | doaj-art-54d87bd5fced48bc8bcbc82c1e47bee8 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-54d87bd5fced48bc8bcbc82c1e47bee82024-11-28T18:10:13ZengBMJ Publishing GroupBMJ Open2044-60552019-09-019910.1136/bmjopen-2018-026136Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysisJinhui Tian0Guanlin Yang1Zhen Hua2Peng Xu3Feng-Ting Zhai4Cheng-Fei Gao5Fan Zhang6Si-jia Liu7Kun Dong8Xiao-Feng Du912 Key Laboratory of Evidence Based Medicine of Gansu Province, Lanzhou, China9 Liaoning University of Traditional Chinese Medicine, Shenyang, ChinaSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China4 Center of Neonatal Disease Screening, Jining Maternal and Child Health Care Hospital, Jining, China2 The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China4 Center of Rehabilitation Medicine, Sichuan University, Chengdu, ChinaDepartment of Nephrology, Long Hua Hospital, Shanghai, China8 Liaoning Traditional Chinese Medicine of Jiahe, Shenyang, China9 Liaoning University of Traditional Chinese Medicine, Shenyang, China9 Liaoning University of Traditional Chinese Medicine, Shenyang, ChinaIntroduction Achieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for treatment. This study aims to examine the comparative effectiveness and safety of oral Chinese patent medicines for UAP on the national essential drugs list of China.Methods and analysis We will conduct a network meta-analysis (NMA) of all randomised controlled trials to evaluate the use of oral Chinese patent medicines as adjuvant for the treatment of UAP. We will explore eight electronic databases from their inception to June 2018 and search for grey literature. Primary outcomes include mortality and the cardiovascular events. Secondary outcomes include: (1) symptom improvement; (2) ECG improvement; (3) frequency of acute angina attack; (4) duration of angina; (5) adverse effects. Two independent authors will screen titles and abstracts, review full texts, extract data, assess the risk of bias using the Cochrane risk of bias tool and assess the quality of evidence and strength of the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). If adequate data are available, NMA will be performed with Bayesian analysis methods.Ethics and dissemination The NMA will help us to reduce the uncertainty of interventions and help clinicians to make optimal and more accurate therapeutic decisions for adults with UAP. Therefore, we will publish the findings of this study in a peer-reviewed journal. No ethics approval is necessary for this study based on the nature of its design.Trial registration number CRD42018092822.https://bmjopen.bmj.com/content/9/9/e026136.full |
| spellingShingle | Jinhui Tian Guanlin Yang Zhen Hua Peng Xu Feng-Ting Zhai Cheng-Fei Gao Fan Zhang Si-jia Liu Kun Dong Xiao-Feng Du Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis BMJ Open |
| title | Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis |
| title_full | Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis |
| title_fullStr | Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis |
| title_full_unstemmed | Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis |
| title_short | Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis |
| title_sort | effectiveness and safety of oral chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of china a protocol for a systematic review and network meta analysis |
| url | https://bmjopen.bmj.com/content/9/9/e026136.full |
| work_keys_str_mv | AT jinhuitian effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT guanlinyang effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT zhenhua effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT pengxu effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT fengtingzhai effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT chengfeigao effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT fanzhang effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT sijialiu effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT kundong effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis AT xiaofengdu effectivenessandsafetyoforalchinesepatentmedicinesasadjuvanttreatmentforunstableanginapectorisonthenationalessentialdrugslistofchinaaprotocolforasystematicreviewandnetworkmetaanalysis |